In this study, we aim to investigate whether enhancing the number of Tregs through the administration of IL‐2:IL‐2 antibody complex (IL‐2:IL‐2 Ab) could improve long‐term neurological recovery after ischemic stroke and the underlying mechanisms, thereby providing novel targets and innovative solutions for stroke treatment. This evidence concerns the gene IL2 and Stroke.